Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03717883 · ClinicalTrials.gov registry record
ADPKD Alterations in Hepatic Transporter Function
A clinical trial, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 24
- Enrollment target
NCT03717883: Completed study, sponsored by University of North Carolina, Chapel Hill.
NCT03717883 is a clinical trial that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03717883 has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 24 participants
- Enrollment target
Study Summary
This is a single center, comparative cohort study to investigate alterations in hepatic transporter function in subjects with autosomal dominant polycystic kidney disease (ADPKD) compared to healthy subjects and subjects with non-ADPKD renal disease. Eligible subjects will be 18-65 years of age and of any race/ethnicity and gender.
Primary Outcome
nmol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2018-09-17 |
| Est. Completion | 2020-01-29 |
What the finished NCT03717883 record still lists
NCT03717883 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 24 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03717883 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03717883 about?
NCT03717883 is a clinical study titled "ADPKD Alterations in Hepatic Transporter Function". This is a single center, comparative cohort study to investigate alterations in hepatic transporter function in subjects with autosomal dominant polycystic kidney disease (ADPKD) compared to healthy subjects and subjects with non-ADPKD renal disease. Eligible subjects will be 18-65 years of age and ...
What is the current status of trial NCT03717883?
This trial is currently completed. The enrollment target is 24 participants. The study started on 2018-09-17. Estimated completion is 2020-01-29.
Who is sponsoring clinical trial NCT03717883?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI